STOCK TITAN

[8-K] Vivakor, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Vivakor, Inc. (VIVK) completed a registered direct offering, selling 10,909,090 shares of common stock at $0.22 per share and 5,000,000 pre-funded warrants at $0.219 for aggregate gross proceeds of approximately $3.5 million. The company plans to use the net proceeds for working capital and general corporate purposes.

The pre-funded warrants are immediately exercisable at $0.001 per share and include ownership caps that limit a holder’s beneficial ownership to 4.99%, or 9.99% if elected prior to issuance. The transaction closed on October 27, 2025. Vivakor paid the placement agent a 7% cash fee on gross proceeds, a 1% non-accountable expense, and reimbursed certain expenses, and conducted the sale under its effective Form S-3 shelf with a prospectus supplement dated October 27, 2025.

Vivakor, Inc. (VIVK) ha completato un'offerta diretta registrata, vendendo 10.909.090 azioni ordinarie a $0,22 ciascuna e 5.000.000 warrant pre-fundati a $0,219 per azione per un ricavo lordo complessivo di circa $3,5 milioni. La società intende utilizzare gli proventi netti per capitale circolante e scopi generali societari.

I warrant pre-fundati sono immediatamente esercitabili a $0,001 per azione e includono limiti di proprietà che limitano la proprietà benefica dell'intestatario al 4,99%, o al 9,99% se scelto prima dell'emissione. La transazione si è chiusa il 27 ottobre 2025. Vivakor ha pagato all'agente di collocamento una commissione in contanti del 7% sui proventi lordi, una spesa non imputabile dell'1% e rimborso di alcune spese, e ha condotto la vendita nell'ambito della sua shelf efficace Form S-3 con un supplemento di prospetto datato 27 ottobre 2025.

Vivakor, Inc. (VIVK) completó una oferta directa registrada, vendiendo 10.909.090 acciones comunes a $0,22 por acción y 5.000.000 warrants prefinanciados a $0,219 por acción para ingresos brutos agregados de aproximadamente $3,5 millones. La empresa planea usar los ingresos netos para capital de trabajo y fines corporativos generales.

Los warrants prefinanciados son ejercibles de inmediato a $0,001 por acción e incluyen límites de propiedad que limitan la participación beneficiosa del titular al 4,99%, o al 9,99% si se elige antes de la emisión. La operación se cerró el 27 de octubre de 2025. Vivakor pagó al agente de colocación una comisión en efectivo del 7% sobre los ingresos brutos, un gasto no reembolsable del 1% y reembolsó ciertos gastos, y llevó a cabo la venta bajo su registro Form S-3 vigente con un suplemento de prospecto fechado el 27 de octubre de 2025.

Vivakor, Inc. (VIVK)는 등록된 직접 공모를 완료했고, 보통주 10,909,090주를 주당 $0.22에, 사전 펀딩 워런트를 5,000,000주를 주당 $0.219에 매각하여 총 매출액은 약 $3.5백만 달러에 이릅니다. 회사는 순매출을 운용자본 및 일반 기업 목적에 사용할 계획입니다.

사전 펀딩 워런트는 즉시 행사 가능하고 주당 $0.001이며, 보유 지분 상한은 소유자의 지분을 4.99%로 제한하거나 발행 전 선택 시 9.99%로 제한합니다. 거래는 2025년 10월 27일에 마감되었습니다. Vivakor는 총수익의 7%를 현금 수수료로, 1%의 비책정 비용을 지급하고 일부 비용을 상환했으며, 2025년 10월 27일 날짜의 Prospectus 보충서가 있는 유효 Form S-3 Shelf 하에서 판매를 실행했습니다.

Vivakor, Inc. (VIVK) a terminé une offre directe enregistrée, vendant 10 909 090 actions ordinaires à 0,22 $ par action et 5 000 000 bons de pré-financement à 0,219 $ par action pour un produit brut total d’environ 3,5 millions de dollars. L’entreprise prévoit d’utiliser le produit net pour le fonds de roulement et les besoins généraux de l’entreprise.

Les bons de pré-financement sont immédiatement exerçables à 0,001 $ par action et incluent des plafonds de propriété qui limitent la participation bénéficiaire d’un détenteur à 4,99 %, ou à 9,99 % s’il est élu avant l’émission. La transaction a été clôturée le 27 octobre 2025. Vivakor a versé à l’agent de placement une commission en espèces de 7 % sur les recettes brutes, une dépense non imputable de 1 % et le remboursement de certaines dépenses, et a mené la vente dans le cadre de son shelf Form S-3 en vigueur avec un supplément de prospectus daté du 27 octobre 2025.

Vivakor, Inc. (VIVK) hat eine registrierte Direktangebot abgeschlossen und 10.909.090 Stammaktien zu 0,22 $ pro Aktie sowie 5.000.000 vorfinanzierte Warrants zu 0,219 $ pro Aktie verkauft, was Bruttoerlöse in Höhe von ca. 3,5 Mio. $ ergibt. Das Unternehmen plant, die Nettoprovent wieder für Working Capital und allgemeine Unternehmenszwecke zu verwenden.

Die vorfinanzierten Warrants sind sofort ausübbar zu 0,001 $ pro Aktie und enthalten Eigentumsobergrenzen, die die beherrschende Eigentümerschaft eines Inhabers auf 4,99 % oder 9,99 % begrenzen, wenn sie vor der Ausgabe gewählt wurden. Der Abschluss der Transaktion erfolgte am 27. Oktober 2025. Vivakor zahlte dem Platzierungsagenten eine Bargeldgebühr von 7 % der Bruttoerlöse, eine 1 %ige nicht erstattbare Gebühr und erstattete bestimmte Ausgaben und führte den Verkauf unter ihrer geltenden Form S-3 Shelf mit einem Prospektzuschlag datiert vom 27. Oktober 2025 durch.

Vivakor, Inc. (VIVK) أكملت عرضاً مباشراً مسجلاً، ببيع 10,909,090 سهماً عادياً بسعر 0.22 دولار للسهم و5,000,000 من خطابات ما قبل التمويل بسعر 0.219 دولار للسهم لإيرادات إجمالية تقارب 3.5 مليون دولار. تخطط الشركة لاستخدام صافي العائدات في رأس المال العامل ولأغراض عامة للشركة.

خطابات ما قبل التمويل قابلة للتسييل فوراً بسعر 0.001 دولار للسهم وتحتوي على حدود ملكية تقيد الملكية المفيدة للمُمسك إلى 4.99%، أو 9.99% إذا تم اختيارها قبل الإصدار. أنجزت الصفقة في 27 أكتوبر 2025. دفعت Vivakor لوكيل الإطلاق عمولة نقدية بنسبة 7% من العائدات الإجمالية، ومصروفاً غير قابل للإرجاع بنسبة 1%، وأجرت تعويضات عن بعض المصروفات، وأجرت البيع بموجب سجل Form S-3 الفعّال مع ملحق نشرة بتاريخ 27 أكتوبر 2025.

Positive
  • None.
Negative
  • None.

Insights

Neutral capital raise: $3.5M gross via shares and pre-funded warrants.

Vivakor executed a primary, registered direct offering for aggregate gross proceeds of $3.5 million, issuing common shares at $0.22 and pre-funded warrants at $0.219. Pre-funded warrants are immediately exercisable at $0.001 per share, a standard structure that front-loads cash proceeds while deferring share issuance mechanics.

The warrants include a Beneficial Ownership Limitation of 4.99% (or 9.99% if elected), which can moderate instantaneous ownership concentration. The company states proceeds will be used for working capital and general corporate purposes; specific deployment is not detailed in the excerpt.

Transaction costs include a 7% cash fee to the placement agent plus a 1% non-accountable expense and reimbursed expenses. The offering closed on October 27, 2025 under an effective S-3 and a prospectus supplement dated October 27, 2025.

Vivakor, Inc. (VIVK) ha completato un'offerta diretta registrata, vendendo 10.909.090 azioni ordinarie a $0,22 ciascuna e 5.000.000 warrant pre-fundati a $0,219 per azione per un ricavo lordo complessivo di circa $3,5 milioni. La società intende utilizzare gli proventi netti per capitale circolante e scopi generali societari.

I warrant pre-fundati sono immediatamente esercitabili a $0,001 per azione e includono limiti di proprietà che limitano la proprietà benefica dell'intestatario al 4,99%, o al 9,99% se scelto prima dell'emissione. La transazione si è chiusa il 27 ottobre 2025. Vivakor ha pagato all'agente di collocamento una commissione in contanti del 7% sui proventi lordi, una spesa non imputabile dell'1% e rimborso di alcune spese, e ha condotto la vendita nell'ambito della sua shelf efficace Form S-3 con un supplemento di prospetto datato 27 ottobre 2025.

Vivakor, Inc. (VIVK) completó una oferta directa registrada, vendiendo 10.909.090 acciones comunes a $0,22 por acción y 5.000.000 warrants prefinanciados a $0,219 por acción para ingresos brutos agregados de aproximadamente $3,5 millones. La empresa planea usar los ingresos netos para capital de trabajo y fines corporativos generales.

Los warrants prefinanciados son ejercibles de inmediato a $0,001 por acción e incluyen límites de propiedad que limitan la participación beneficiosa del titular al 4,99%, o al 9,99% si se elige antes de la emisión. La operación se cerró el 27 de octubre de 2025. Vivakor pagó al agente de colocación una comisión en efectivo del 7% sobre los ingresos brutos, un gasto no reembolsable del 1% y reembolsó ciertos gastos, y llevó a cabo la venta bajo su registro Form S-3 vigente con un suplemento de prospecto fechado el 27 de octubre de 2025.

Vivakor, Inc. (VIVK)는 등록된 직접 공모를 완료했고, 보통주 10,909,090주를 주당 $0.22에, 사전 펀딩 워런트를 5,000,000주를 주당 $0.219에 매각하여 총 매출액은 약 $3.5백만 달러에 이릅니다. 회사는 순매출을 운용자본 및 일반 기업 목적에 사용할 계획입니다.

사전 펀딩 워런트는 즉시 행사 가능하고 주당 $0.001이며, 보유 지분 상한은 소유자의 지분을 4.99%로 제한하거나 발행 전 선택 시 9.99%로 제한합니다. 거래는 2025년 10월 27일에 마감되었습니다. Vivakor는 총수익의 7%를 현금 수수료로, 1%의 비책정 비용을 지급하고 일부 비용을 상환했으며, 2025년 10월 27일 날짜의 Prospectus 보충서가 있는 유효 Form S-3 Shelf 하에서 판매를 실행했습니다.

Vivakor, Inc. (VIVK) a terminé une offre directe enregistrée, vendant 10 909 090 actions ordinaires à 0,22 $ par action et 5 000 000 bons de pré-financement à 0,219 $ par action pour un produit brut total d’environ 3,5 millions de dollars. L’entreprise prévoit d’utiliser le produit net pour le fonds de roulement et les besoins généraux de l’entreprise.

Les bons de pré-financement sont immédiatement exerçables à 0,001 $ par action et incluent des plafonds de propriété qui limitent la participation bénéficiaire d’un détenteur à 4,99 %, ou à 9,99 % s’il est élu avant l’émission. La transaction a été clôturée le 27 octobre 2025. Vivakor a versé à l’agent de placement une commission en espèces de 7 % sur les recettes brutes, une dépense non imputable de 1 % et le remboursement de certaines dépenses, et a mené la vente dans le cadre de son shelf Form S-3 en vigueur avec un supplément de prospectus daté du 27 octobre 2025.

Vivakor, Inc. (VIVK) hat eine registrierte Direktangebot abgeschlossen und 10.909.090 Stammaktien zu 0,22 $ pro Aktie sowie 5.000.000 vorfinanzierte Warrants zu 0,219 $ pro Aktie verkauft, was Bruttoerlöse in Höhe von ca. 3,5 Mio. $ ergibt. Das Unternehmen plant, die Nettoprovent wieder für Working Capital und allgemeine Unternehmenszwecke zu verwenden.

Die vorfinanzierten Warrants sind sofort ausübbar zu 0,001 $ pro Aktie und enthalten Eigentumsobergrenzen, die die beherrschende Eigentümerschaft eines Inhabers auf 4,99 % oder 9,99 % begrenzen, wenn sie vor der Ausgabe gewählt wurden. Der Abschluss der Transaktion erfolgte am 27. Oktober 2025. Vivakor zahlte dem Platzierungsagenten eine Bargeldgebühr von 7 % der Bruttoerlöse, eine 1 %ige nicht erstattbare Gebühr und erstattete bestimmte Ausgaben und führte den Verkauf unter ihrer geltenden Form S-3 Shelf mit einem Prospektzuschlag datiert vom 27. Oktober 2025 durch.

Vivakor, Inc. (VIVK) أكملت عرضاً مباشراً مسجلاً، ببيع 10,909,090 سهماً عادياً بسعر 0.22 دولار للسهم و5,000,000 من خطابات ما قبل التمويل بسعر 0.219 دولار للسهم لإيرادات إجمالية تقارب 3.5 مليون دولار. تخطط الشركة لاستخدام صافي العائدات في رأس المال العامل ولأغراض عامة للشركة.

خطابات ما قبل التمويل قابلة للتسييل فوراً بسعر 0.001 دولار للسهم وتحتوي على حدود ملكية تقيد الملكية المفيدة للمُمسك إلى 4.99%، أو 9.99% إذا تم اختيارها قبل الإصدار. أنجزت الصفقة في 27 أكتوبر 2025. دفعت Vivakor لوكيل الإطلاق عمولة نقدية بنسبة 7% من العائدات الإجمالية، ومصروفاً غير قابل للإرجاع بنسبة 1%، وأجرت تعويضات عن بعض المصروفات، وأجرت البيع بموجب سجل Form S-3 الفعّال مع ملحق نشرة بتاريخ 27 أكتوبر 2025.

Vivakor, Inc. (VIVK) 完成了一项注册直接发行,出售 10,909,090 股普通股,股价为每股 0.22 美元,以及 5,000,000 股预先融资权证,价格为每股 0.219 美元,总毛收入约 350 万美元。公司计划将净收益用于运营资金和一般企业用途。

预先融资权证可立即按每股 0.001 美元行使,并包含所有权上限,限制持有人的实际控制权不超过 4.99%,若在发行前被选定则为 9.99%。交易于 2025 年 10 月 27 日结束。Vivakor 向配售代理支付了毛额募资的 7% 现金费用、1% 不可核算费用,并偿还了部分费用,并在其有效的 Form S-3 基础上进行交易,招股说明书补充文件日期为 2025 年 10 月 27 日。

false 0001450704 0001450704 2025-10-24 2025-10-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 24, 2025

 

VIVAKOR, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-41286   26-2178141
(State or other jurisdiction of   (Commission   (IRS Employer
incorporation or organization)   File Number)   Identification No.)

 

5220 Spring Valley Road, Suite 500

Dallas, TX 75254

(Address of principal executive offices)

 

(469) 480-7175

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   VIVK   The Nasdaq Stock Market LLC
(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 

 

 

Item 1.01 Entry Into Material Definitive Agreement.

 

On October 24, 2025, Vivakor, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a registered direct offering (A) an aggregate of 10,909,090 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, at an offering price of $0.22 per share, and (B) 5,000,000 pre-funded warrants (the “Pre-Funded Warrants”) in lieu of shares of Common Stock, at an offering price of $0.219 (such registered direct offering, the “Offering”) for aggregate gross proceeds of approximately $3.5 million, before deducting Offering expenses payable by the Company, including the Placement Agent’s commissions and fees. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes. The Offering closed on October 27, 2025.

 

The Pre-Funded Warrants are immediately exercisable and may be exercised at a nominal consideration of $0.001 per share of Common Stock at any time until all of the Pre-Funded Warrants are exercised in full.

 

The Pre-Funded Warrants contain ownership limitations pursuant to which a holder does not have the right to exercise any portion of their warrants if it would result in the holder (together with its affiliates) beneficially owning more than 4.99% (or, upon election by the holder prior to the issuance of any warrants, 9.99%) of the Company’s outstanding Common Stock.

 

In connection with the Offering, the Company also entered into a placement agency agreement (the “Placement Agency Agreement”) with D. Boral Capital LLC (the “Placement Agent”), pursuant to which the Company paid the Placement Agent (i) a cash fee equal to 7% of the aggregate gross proceeds of the Offering, (ii) one percent (1.0%) of the gross proceeds of the Offering for non-accountable expenses, and (iii) reimbursed the Placement Agent for certain expenses and legal fees.

 

The Common Shares, the Pre-Funded Warrants and the shares of Common Stock underlying the Pre-Funded Warrants were offered pursuant to a “shelf” registration statement on Form S-3 (File No. 333-269178) that was declared effective by the Securities and Exchange Commission (the “Commission”) on February 10, 2023 and a prospectus supplement dated October 27, 2025, which was filed with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended.

 

The forms of the Purchase Agreement, Placement Agency Agreement and Pre-Funded Warrant are filed as exhibits to this Current Report on Form 8-K (this “Form 8-K”) and are incorporated by reference herein.

 

ITEM 8.01 Other Events.

 

On October 24, 2025, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

 

 1 

 

 

ITEM 9.01 Financial Statements and Exhibits.

 

(d)Exhibits

 

Exhibit No.   Title
4.1   Form of Pre-Funded Warrant
5.1   Legal Opinion of Lucosky Brookman LLP
10.1   Form of Securities Purchase Agreement
10.2   Form of Placement Agency Agreement
99.1   Press Release, dated October 24, 2025
104   Cover Page Interactive Data File (formatted as Inline XBRL).

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VIVAKOR, INC.
     
Dated: October 27, 2025 By: /s/ James H. Ballengee
    Name: James H. Ballengee
    Title: Chairman, President & CEO

 

 3 

FAQ

What did VIVK announce in its 8-K?

Vivakor completed a registered direct offering of 10,909,090 common shares at $0.22 and 5,000,000 pre-funded warrants at $0.219 for approximately $3.5 million in gross proceeds.

What are the terms of VIVK’s pre-funded warrants?

They are immediately exercisable at $0.001 per share and include ownership limits of 4.99%, or 9.99% if elected prior to issuance.

How will Vivakor use the offering proceeds?

The company plans to use net proceeds for working capital and general corporate purposes.

When did the VIVK offering close?

The offering closed on October 27, 2025.

What fees were paid to the placement agent?

Vivakor paid a 7% cash fee on gross proceeds, a 1% non-accountable expense, and reimbursed certain expenses and legal fees.

Under what registration was the offering made?

The securities were offered under an effective Form S-3 (File No. 333-269178) and a prospectus supplement dated October 27, 2025.
Vivakor

NASDAQ:VIVK

VIVK Rankings

VIVK Latest News

VIVK Latest SEC Filings

VIVK Stock Data

25.27M
60.80M
54.06%
10.47%
0.32%
Oil & Gas Integrated
Refuse Systems
Link
United States
DALLAS